ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1618

Chromatin Binding In SLE Patients Correlates With The Intensity Of Apoptotic Binding By 9G4+ B Cells

Asiya Seema Chida1, Quan-Zhen Li2, Chandra Mohan3, Youliang Wang1, Scott Jenks4, Louise Hartson1 and Ignacio Sanz5, 1Medicine, Emory University Medical Center, Atlanta, GA, 2Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, 3University of Houston, Houston, TX, 4Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, 5Rheumatology, Emory University, Atlanta, GA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: apoptotic clearance, autoantibodies, nucleosomes and pathogenesis, SLE

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus-Human Etiology and Pathogenesis: Genetics and Genomics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic Lupus Erythematosus (SLE) is a multi-organ autoimmune disease characterised by production of autoantibodies to multiple nuclear antigens, some of which are highly specific for SLE including anti-ds DNA, anti-Smith and anti-nucleosome antibodies. IgG antibodies expressing the 9G4 idiotype, encoded by the framework-1 hydrophobic patch (HP) of VH4-34, are specifically expanded in SLE and provide a unique model to understand the participation of different autoantigens in the pathogenesis of this disease.  9G4 autoreactivity may be directed against different lupus antigens and accounts for a significant fraction of anti-apoptotic cell binding (APCB), of lupus serum.  Here we sought to understand the contribution of anti-nucleosome reactivity to APCB.  

Methods:

A panel of 9G4+ monoclonal antibodies was generated from IgD-CD27+ memory cells of SLE patients.  APCB was determined by flow cytometry.  Positive and negative binders for Apoptotic binding were tested for anti-Chromatin reactivity by ELISA.  Three representative antibodies with strong APCB activity were also tested against a glomerular proteome antigen microarray.

 

Results:

Our preliminary data demonstrate a strong correlation of apoptotic binding with chromatin by ELISA. Out of 37 9G4+ monoclonals tested 10 were positive for apoptotic binding and  out of these 10, 9 were positive for chromatin (p=<0.001; fisher exact test). Glomerular microarray analysis identified reactivity with Chromatin, histones H2A, H2B, H3 and H4 in different patterns for the individual antibodies.  This assay also identified interesting patterns of polyreactivity against of other lupus antigens including Riboprotein P1, but not P0 or P2, U1-RNP and Sm.  Of note, these patterns reflected the reactivity of the patients serum.   Levels of reactivity against chromatin, H2A, H2B, H3, and U1-Sn-RNP-68 correlated with disease activity.   

Conclusion:

SLE-specific 9G4 antibodies recognize nucleosomal antigens (chromatin and individual histones) and may be polyreactive against components of the snRNP complex.  Both these types of antigens are expressed at high density on apoptotic cells which are highly immunogenic sources of self-antigens in SLE at least in part due to deficient clearance.  Detailed structural, antigenic and functional studies of our mAbs should shed significant light into the triggering of these autoimmune responses and the role of different antigens in the shaping and selection of the autoimmune B cell memory compartment.  Determination of 9G4 antibodies against apoptotic cells and/or nucleosomal antigens might provide a useful test for the diagnosis and monitorization of SLE.


Disclosure:

A. S. Chida,
None;

Q. Z. Li,
None;

C. Mohan,
None;

Y. Wang,
None;

S. Jenks,
None;

L. Hartson,
None;

I. Sanz,

Biogen Idec,

2,

Pfizer Inc,

9.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chromatin-binding-in-sle-patients-correlates-with-the-intensity-of-apoptotic-binding-by-9g4-b-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology